COMMUNIQUÉS West-GlobeNewswire

-
Hua Medicine Raises $117.4 Million in Series D & Series E Financing
27/03/2018 -
BioStem Technologies, Inc. Announces Letter of Intent with CCM Pharma Solutions to Co-Develop Multiple Solid to Liquid Dose Drugs Through 505(b)(2) Accelerated FDA Approval Process
27/03/2018 -
R1 Appoints Alex Mandl as Lead Director
26/03/2018 -
Matinas BioPharma Reports 2017 Financial Results
26/03/2018 -
Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
26/03/2018 -
Intercept to Present at Upcoming Conference
26/03/2018 -
Quotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction
26/03/2018 -
Eyenovia Appoints Three Industry Veterans to Board of Directors
26/03/2018 -
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
26/03/2018 -
Quotient Limited Announces Retirement of Paul Cowan, Chairman and Chief Executive Officer; Franz Walt Named as Interim Chief Executive Officer
26/03/2018 -
Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website
26/03/2018 -
DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering
26/03/2018 -
DBV Technologies annonce le règlement-livraison des actions ordinaires supplémentaires au titre de l'exercice de la totalité de l'option de surallocation dans le cadre de son offre globale
26/03/2018 -
argenx announces Annual General Meeting of Shareholders on May 8, 2018
26/03/2018 -
MacroGenics Announces Proposed Public Offering of Common Stock
26/03/2018 -
Profound Medical Corp. Announces Fourth Quarter and Full Year 2017 Financial Results
26/03/2018 -
CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property
26/03/2018 -
Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
26/03/2018 -
Stage 3 Meaningful Use Certification Achieved by PracticeSuite EHR
26/03/2018
Pages